Pfizer (PFE) FDA Approves XALKORI for Lung Cancer

Pfizer Incorporated - symbol PFE - reported that the U.S. Food and Drug Administration has approved its XALKORI. the first-ever therapy targeting anaplastic lymphoma kinase, for the treatment of patients with locally advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase-positive as detected by an FDA-approved test.